Sawyer & Company’s Emergent Biosolutions EBS Stock Holding History

Sawyer & Company’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15	Closed	–	–	180
2024 Q3	$0	Hold	15	–	–	﹤0.01%	194
2024 Q2	$0	Buy	+15	New	+$65	﹤0.01%	175

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OHA

Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

Sawyer & Company's EBS Position: Q4 2024 in Review

Sawyer & Company sold out of Emergent Biosolutions (EBS) in Q4 2024, closing a stake of 15 shares.

Sawyer & Company first reported a position in EBS in Q2 2024 and held it in 2 quarters. The position peaked at $0 in Q3 2024. 156 funds tracked by Wall St. Rank hold EBS as of Q4 2024.

Sawyer & Company reported no remaining Emergent Biosolutions position as of Q4 2024 after selling out during the quarter.
Sawyer & Company sold 15 Emergent Biosolutions shares in Q4 2024.
Sawyer & Company first reported a position in Emergent Biosolutions in Q2 2024 and held it in 2 quarters.
Sawyer & Company's Emergent Biosolutions position peaked at $0 in Q3 2024.
156 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2024.

Based on Sawyer & Company's 13F filing for Q4 2024, filed 14 Jan 2025.